191 related articles for article (PubMed ID: 36936141)
1. Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas.
Zhang Y; Li L; Ma X; Liu C; Liu G; Bie Z; Yang Z; Liu P
Front Endocrinol (Lausanne); 2023; 14():1137648. PubMed ID: 36936141
[TBL] [Abstract][Full Text] [Related]
2. TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas.
Wang Y; Cheng T; Lu M; Mu Y; Li B; Li X; Zhan X
EPMA J; 2019 Dec; 10(4):395-414. PubMed ID: 31832114
[TBL] [Abstract][Full Text] [Related]
3. Identification of HSPD1 as a novel invasive biomarker associated with mitophagy in pituitary adenomas.
Zhang Y; Ma X; Liu C; Bie Z; Liu G; Liu P; Yang Z
Transl Oncol; 2024 Mar; 41():101886. PubMed ID: 38290248
[TBL] [Abstract][Full Text] [Related]
4. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
5. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
Wang J; Zhang Z; Li R; Mao F; Sun W; Chen J; Zhang H; Bartsch JW; Shu K; Lei T
Biomed Pharmacother; 2018 Jan; 97():1066-1077. PubMed ID: 29136943
[TBL] [Abstract][Full Text] [Related]
6. Fascin promotes the invasion of pituitary adenoma through partial dependence on epithelial-mesenchymal transition.
You H; Xu J; Qin X; Qian G; Wang Y; Chen F; Shen X; Zhao D; Liu Q
J Mol Histol; 2021 Aug; 52(4):823-838. PubMed ID: 34097178
[TBL] [Abstract][Full Text] [Related]
7. Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.
Yu SY; Hong LC; Feng J; Wu YT; Zhang YZ
Tumour Biol; 2016 Jul; 37(7):8923-30. PubMed ID: 26753958
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.
Zhan X; Wang X; Long Y; Desiderio DM
BMC Med Genomics; 2014 Dec; 7():69. PubMed ID: 25539738
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal Transition (EMT) Markers in Human Pituitary Adenomas Indicate a Clinical Course.
Jia W; Zhu J; Martin TA; Jiang A; Sanders AJ; Jiang WG
Anticancer Res; 2015 May; 35(5):2635-43. PubMed ID: 25964539
[TBL] [Abstract][Full Text] [Related]
10. Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives.
Zhan X; Desiderio DM
Mass Spectrom Rev; 2005; 24(6):783-813. PubMed ID: 15495141
[TBL] [Abstract][Full Text] [Related]
11. Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.
Feng J; Hong L; Wu Y; Li C; Wan H; Li G; Sun Y; Yu S; Chittiboina P; Montgomery B; Zhuang Z; Zhang Y
J Neurooncol; 2014 Sep; 119(2):307-15. PubMed ID: 24916845
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.
Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of invasive non-functional pituitary adenomas using exosomal biomarkers.
Ren Y; Wang Y; Bao X; Feng M; Xing B; Lian W; Yao Y; Wang R
Clin Chim Acta; 2022 Apr; 529():25-33. PubMed ID: 35085587
[TBL] [Abstract][Full Text] [Related]
14. Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.
Chen L; Liu Y; Hou Y; Kato Y; Sano H; Kanno T
Neurosci Lett; 2007 Apr; 417(1):30-5. PubMed ID: 17398005
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
[TBL] [Abstract][Full Text] [Related]
16. A novel risk model based on the correlation between the expression of basement membrane genes and immune infiltration to predict the invasiveness of pituitary adenomas.
Chen Z; Sun X; Kang Y; Zhang J; Jia F; Liu X; Zhu H
Front Endocrinol (Lausanne); 2022; 13():1079777. PubMed ID: 36686480
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.
Hosseinkhan N; Honardoost M; Emami Z; Cheraghi S; Hashemi-Madani N; Khamseh ME
Endocrine; 2022 Sep; 77(3):500-509. PubMed ID: 35711030
[TBL] [Abstract][Full Text] [Related]
18. Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas.
Zhan X; Desiderio DM; Wang X; Zhan X; Guo T; Li M; Peng F; Chen X; Yang H; Zhang P; Li X; Chen Z
Electrophoresis; 2014 Aug; 35(15):2184-94. PubMed ID: 24729304
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of doublecortin (DCX) in pituitary adenoma.
Liu X; Ma L; Wang Z; Ye J; Liu X; Jiang G; Wang H
Bull Cancer; 2019 Dec; 106(12):1080-1085. PubMed ID: 31376915
[TBL] [Abstract][Full Text] [Related]
20. Regulating effect of MMP-9 and TIMP-1 in pituitary adenoma invasion.
Mao JH; Guo H; Si N; Qiu L; Guo LF; Sun ZS; Xiang Y; Yang XH; Zhao WG; Zhang WC
Genet Mol Res; 2015 Dec; 14(4):17091-8. PubMed ID: 26681056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
